JD Supra: Mergers

SEPTEMBER 23, 2024

On August 31, the last day of its 2024 Legislative Session, the California Legislature approved Assembly Bill 3129 (Wood), which provides for notification to and review by the Attorney General of health care transactions involving private equity groups and hedge funds.

Private Equity 167

Private Equity Equities Healthcare Funds 167

How2Exit

NOVEMBER 11, 2024

E256: Why Private Equity is Hungry for Small Businesses – Here's How You Can Cash In - Watch Here About the Guest(s): Adam Coffey is a renowned CEO specializing in running private equity companies, a best-selling author, and a veteran in the business industry. billion in exits.

Private Equity 130

Private Equity Equities Business Book-building 130

JD Supra: Mergers

SEPTEMBER 10, 2024

For the sixth consecutive year, Dechert is the contributing editor of the International Comparative Legal Guide - Private Equity.

Private Equity 149

Private Equity Equities Government IT 149

JD Supra: Mergers

NOVEMBER 5, 2024

The changes to 13 CFR § 121.404 are of significance to companies such as private equity firms seeking to acquire small business contractors. By: McDermott Will & Emery

Private Equity 167

Private Equity Equities Government Mergers 167

JD Supra: Mergers

SEPTEMBER 26, 2024

The California Legislature recently passed Assembly Bill 3129 (“AB 3129” or the “Bill”), which, if signed by California Governor Gavin Newsom, would increase oversight of healthcare entity transactions involving private equity investment. Governor Newsom has until September 30, 2024, to sign or veto the Bill.

Private Equity 172

Private Equity Healthcare Equities Investment 172

JD Supra: Mergers

NOVEMBER 1, 2024

To help businesses, investors, and deal professionals better understand the evolving private equity landscape in the lower middle market, Rob Connolly – a partner in and leader of LP’s Corporate Practice Group – shares a series of conversations with private equity firms and professionals. By: Levenfeld Pearlstein, LLC

Private Equity 167

Private Equity Equities Middle Market Capital 167

JD Supra: Mergers

JUNE 3, 2024

Private equity firms can breathe a sigh of relief after a federal judge dismissed claims that threatened to establish a precedent for holding private equity firms liable for certain actions by their portfolio companies. By: Troutman Pepper

Private Equity 172

Private Equity Equities Portfolio 172

JD Supra: Mergers

OCTOBER 1, 2024

Gavin Newsom vetoed a controversial bill that would have restricted private equity and hedge fund healthcare transactions in the state. On Saturday, September 28, California Gov. By: Fenwick & West LLP

Private Equity 161

Private Equity Healthcare Equities Funds 161

JD Supra: Mergers

OCTOBER 15, 2024

According to EY’s Private Equity Pulse, Q2 2024 was the strongest quarter in two years, with 122 announced transactions at a valuation of $196 billion total enterprise value. This seems to be the case, as we see initial signs of an improving landscape after a stronger Q2. But the US PE market is. By: Woodruff Sawyer

Private Equity 172

Private Equity Equities Insurance Valuation 172

JD Supra: Mergers

OCTOBER 1, 2024

INTRODUCTION TO HR RISKS IN PE INVESTMENTS - Private equity (PE) investments in Germany present unique challenges and opportunities, particularly from a human resources (HR) perspective.

Private Equity 161

Private Equity Equities Investment Capital 161

JD Supra: Mergers

AUGUST 2, 2024

Venable's Private Equity Investment in Healthcare webinar series explores the unique issues and timely developments that shape deals within the industry. Investment in the healthcare industry requires careful consideration, as it involves numerous distinct areas of the law. By: Venable LLP

Private Equity 167

Private Equity Healthcare Equities Investment 167

JD Supra: Mergers

AUGUST 1, 2024

Over the last decade, private equity firms have acquired healthcare companies, hospitals, and clinics at an increasing rate. In fact, in those ten years, private equity firms have spent roughly $1 trillion on an estimated 8,000 healthcare deals. This trend is only expected to increase through 2024.

Private Equity 155

Private Equity Healthcare Equities Portfolio 155

JD Supra: Mergers

OCTOBER 11, 2024

State legislatures across the country are beginning to consider and debate the pros and cons of passing laws aimed at regulating private equity’s role in the healthcare industry. Originally published in The Journal Record - October 10, 2024. By: McAfee & Taft

Private Equity 172

Private Equity Healthcare Equities 172

JD Supra: Mergers

AUGUST 29, 2024

Driven by a growing wave of enforcer skepticism toward further healthcare consolidation, some state legislatures have begun to propose “mini-HSR” laws explicitly targeting healthcare transactions involving private equity firms or sponsors. By: Morgan Lewis

Private Equity 167

Private Equity Healthcare Equities 167

JD Supra: Mergers

OCTOBER 2, 2024

3129 (AB 3129), which would have required private equity groups and hedge funds to obtain the Attorney General’s written consent at least 90 days prior to acquisitions or changes of control of certain health care facilities, provider groups, and other providers. On September 28, 2024, Governor Newsom vetoed Assembly Bill No.

Private Equity 167

Private Equity Equities Healthcare Funds 167

JD Supra: Mergers

MARCH 12, 2024

The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Although overall transaction volume was significantly down, private equity funds still found. By: Akin Gump Strauss Hauer & Feld LLP

Private Equity 192

Private Equity Equities Debt Valuation 192

JD Supra: Mergers

FEBRUARY 28, 2024

Traditionally, private equity firms were seen as benign investors from an antitrust perspective. This is changing. In the past 12 months, PE-funded acquisitions have faced progressively more rigorous scrutiny by antitrust authorities. By: Allen & Overy LLP

Private Equity 187

Private Equity Equities Funds Investors 187

JD Supra: Mergers

OCTOBER 1, 2024

The Bill, if enacted, would have imposed new notice and consent requirements for private equity investors involved in healthcare transactions. On September 28, 2024, California Governor Gavin Newsom vetoed California Assembly Bill 3129 (the Bill). By: Robinson+Cole Health Law Diagnosis

Private Equity 161

Private Equity Healthcare Equities Investors 161

JD Supra: Mergers

SEPTEMBER 19, 2024

As this fall’s election approaches, headwinds have been brewing in DC and state legislatures for private equity health care dealmaking, many of them with bipartisan support.

Private Equity 167

Private Equity Equities Acquisitions 167

JD Supra: Mergers

AUGUST 5, 2024

The Massachusetts legislative session for 2024 has come to a close without the passage of a bill that would have targeted private equity in healthcare.

Private Equity 167

Private Equity Healthcare Equities Funds 167

JD Supra: Mergers

JANUARY 9, 2024

As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector. W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity.

Private Equity 196

Private Equity Healthcare Equities Funds 196

JD Supra: Mergers

OCTOBER 1, 2024

On Saturday, September 28th, Governor Newsom vetoed AB 3129, which would have required pre-closing notice to and, in some instances, approval by the California Attorney General for a wide range of private equity health care transactions in California.

Private Equity 167

Private Equity Equities IT 167

JD Supra: Mergers

AUGUST 1, 2024

At the end of last year, Holland & Knight predicted that "the current enforcement environment will continue into 2024 and will focus heavily on the healthcare industry, along with private equity transactions or 'roll-ups.' 15, 2023.)

Private Equity 167

Private Equity Healthcare Equities 167

JD Supra: Mergers

AUGUST 1, 2024

Private equity investment in health care has grown significantly over the past two decades, and the US government is starting to pay attention. The False Claims Act (FCA) appears to be the first avenue of enforcement, but private equity firms should be prepared for state. By: K&L Gates LLP

Private Equity 172

Private Equity Equities Medical Government 172

JD Supra: Mergers

JUNE 4, 2024

Private equity sponsors can exhale: A federal court recently stopped the Federal Trade Commission's (FTC) antitrust action that targeted private equity sponsor Welsh, Carson, Anderson & Stowe for the healthcare "roll-up" strategy of its anesthesia practice management portfolio company. Anesthesia Partners, Inc.

Private Equity 182

Private Equity Healthcare Equities Portfolio 182

JD Supra: Mergers

NOVEMBER 19, 2024

Key Takeaways from October Deal activity: The final quarter of 2024 did not get off to a strong start in October, but dealmakers remain optimistic that the dealmaking environment will continue to improve and transaction activity will pick up.

Private Equity 172

Private Equity Equities 172

JD Supra: Mergers

MAY 22, 2024

McGuireWoods recently held its 20th Annual Healthcare Private Equity and Finance Conference (HCPE Conference) in Chicago. The conference drew more than 1,000 professionals from private equity funds, senior and mezzanine lenders, and investment banks, as well as C-level executives, consultants and principals in the healthcare industry.

Private Equity 161

Private Equity Healthcare Finance Finance 161

JD Supra: Mergers

JUNE 12, 2024

Episode 7: Exploring the Role of Operating Partners in Private Equity In this episode of BRight Minds in Healthcare Delivery, Donna Cooper joins host Eric Tower for a conversation about her career and how her prior experience has influenced her current role as an operating partner. Donna explains the role of an operating partner at….

Private Equity 161

Private Equity Equities Healthcare 161

JD Supra: Mergers

JULY 25, 2024

2871, An Act Enhancing the Health Care Market Review Process (the Bill), to increase oversight of healthcare transactions involving private equity firms, real estate investment trusts, and management services organizations (MSOs). On July 18, 2024, the Massachusetts Senate passed S. By: Sheppard Mullin Richter & Hampton LLP

Private Equity 167

Private Equity Healthcare Equities Management 167

JD Supra: Mergers

AUGUST 15, 2024

private equity investors has reached an all-time high, and with capital on the sideline ready to deploy, pressure to get deals done is on the rise. Although the U.S. healthcare industry has weathered the storm over the past couple of years, we may be reaching calmer waters in the coming months. Dry powder held by U.S.

Private Equity 172

Private Equity Healthcare Equities M&A 172

JD Supra: Mergers

MARCH 8, 2024

Private equity is squarely in the cross hairs of regulators; the Department of Justice Antitrust Division, the Federal Trade Commission, and the U.S. Department of Health and Human Services recently announced the launch of a joint inquiry into private equity ownership in the health care field. By: Ballard Spahr LLP

Private Equity 187

Private Equity Equities Acquisitions Trading 187

JD Supra: Mergers

MARCH 12, 2024

Private equity acquisitions in healthcare will likely face increased scrutiny from multiple federal departments, as well as from state antitrust enforcement officials. By: Mayer Brown

Private Equity 177

Private Equity Healthcare Equities Acquisitions 177

JD Supra: Mergers

MARCH 12, 2024

On March 5, the FTC convened a workshop with regulators, academics and stakeholders to discuss the impact of private equity in the healthcare market. The workshop reflects the FTC and DOJ Antitrust Division’s recent focus on private equity and serial roll-up transactions more broadly as targets for antitrust enforcement.

Private Equity 167

Private Equity Healthcare Equities Acquisitions 167

JD Supra: Mergers

AUGUST 29, 2024

Audax Private Equity has announced it will acquire the clinical services business of Avantor (NYSE: AVTR). By: McGuireWoods LLP

Private Equity 149

Private Equity Equities Healthcare Business 149

JD Supra: Mergers

MAY 21, 2024

What do private equity and growth capital investors look for when adding new companies to their portfolio, and what strategies do they apply to help those companies optimize capital? They covered the current private equity landscape, strategies for creating value, industry trends, various investment structures, and more.

Private Equity 167

Private Equity Equities Capital Mergers and Acquisitions 167

JD Supra: Mergers

SEPTEMBER 25, 2023

Federal Trade Commission (“FTC”) antitrust lawsuit against a private-equity owner of a large anesthesiology practice in Texas demonstrates that the FTC has begun to implement its more aggressive focus on the perceived competitive harms caused by certain “roll-up” acquisition strategies.

Private Equity 167

Private Equity Equities Acquisitions Trading 167

JD Supra: Mergers

JULY 8, 2024

During the past 12 years, private equity (PE) firms have served as major investors in the U.S. health care market, participating in acquisitions and consolidations of physician practices across various specialties.

Private Equity 155

Private Equity Economics Equities Investors 155